Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus and the spectrum of the acute syndrome of apoptotic pan-epidermolysis (ASAP): A case report, concept review and proposal for new classification of lupus erythematosus vesiculobullous skin lesions

Lupus

Volumn 13, Issue 12, 2004, Pages 941-950

  Ting, W ^a   Stone, M S ^b   Racila, D ^b   Scofield, R H ^c   Sontheimer, Richard D ^b,d  

^a Dept of Dermatol Camino Med Group ^*  (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Cutaneous lupus erythematosus; Graft versus host disease; Toxic epidermal necrolysis

Indexed keywords

ANTIBIOTIC AGENT; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIPERACILLIN PLUS TAZOBACTAM; RABEPRAZOLE; SULTAMICILLIN; SUNSCREEN; WARFARIN;

ACUTE SYNDROME OF APOPTOTIC PAN EPIDERMOLYSIS; ADULT; APOPTOSIS; BULLOUS SKIN DISEASE; CASE REPORT; CELL DAMAGE; CLINICAL FEATURE; DISEASE CLASSIFICATION; DRUG HYPERSENSITIVITY; EPIDERMIS CELL; EPIDERMOLYSIS; ERYTHEMA; FEMALE; HISTOPATHOLOGY; HUMAN; PRIORITY JOURNAL; REVIEW; SKIN DISEASE; SKIN LUPUS ERYTHEMATOSUS; SKIN PIGMENTATION; SYNDROME DELINEATION; TOXIC EPIDERMAL NECROLYSIS;

ACUTE DISEASE; DIAGNOSIS, DIFFERENTIAL; EPIDERMAL NECROLYSIS, TOXIC; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, CUTANEOUS; MIDDLE AGED; SKIN DISEASES, VESICULOBULLOUS; SYNDROME;

EID: 10844289616     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203304lu2037sa     Document Type: Review

References (75)

1. Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol 1956; 68: 355-361.
2. Sontheimer RD, Gilliam JN. An immunofluorescence assay for double-stranded DNA antibodies using the Crithidia luciliae kinetoplast as a double-stranded DNA substrate. J Lab Clin Med 1978; 91: 550-558.
3. Dickey WD, van Egmond JE, Hardgrave KL, Harley JB, Scofield RH. Presence of anti-La(SS-B) is associated with binding to the 13-kD carboxyl terminus of 60-kD Ro(SS-A) in systemic lupus erythematosus. J Invest Dermatol 1993; 100: 412-416.
4. Scofield RH, Frank MB, Neas BR et al. Cooperative association of T cell beta receptor and HLA-DQ alleles in the production of anti-Ro in systemic lupus erythematosus. Clin Immunol Immunopathol 1994; 72: 335-341.
5. Rowell NR, Swanson-Beck J, Andrewson JR. Lupus erythematosus and erythema multiforme-like lesions. Arch Dermatol 1963; 88: 176-180.
6. Braverman IM. Skin signs of systemic disease. Philadelphia: WB Saunders, 1998.
7. Kelly JP, Auquier A, Rzany B et al. An international collaborative case-control study of severe cutaneous adverse reactions (SCAR). Design and methods. J Clin Epidemiol 1995; 48: 1099-1108.
8. Zappi E, Sontheimer R. Clinical relevance of antibodies to Ro/SS-A and La/SS-B in subacute cutaneous lupus erythematosus and related conditions. Immunol Invest 1993; 22: 189-203.
9. Rondeel JM. Immunofluorescence versus ELISA for the detection of antinuclear antigens. Expert Rev Mol Diagn 2002; 2: 226-232.
10. Griesmacher A, Peichl P. Autoantibodies associated with rheumatic diseases. Clin Chem Lab Med 2001; 39: 189-208.
11. Pedro SD, Dahl MV. Direct immunofluorescence of bullous systemic lupus erythematosus. Arch Dermatol 1973; 107: 118-120.
12. Gammon WR, Briggaman RA. Bullous SLE: a phenotypically distinctive but immunologically heterogeneous bullous disorder. J Invest Dermatol 1993; 100: 28S-34S.
13. Yell JA, Allen J, Wojnarowska F, Kirtschig G, Burge SM. Bullous systemic lupus erythematosus: revised criteria for diagnosis. Br J Dermatol 1995; 132: 921-928.
14. Sontheimer RD. The lexicon of cutaneous lupus erythematosus - a review and personal perspective on the nomenclature and classification of the cutaneous manifestations of lupus erythematosus. Lupus 1997; 6: 84-95.
15. Sontheimer RD. Subacute cutaneous lupus erythematosus. Clin Dermatol 1985; 3: 58-68.
16. Bielsa I, Herrero C, Font J, Mascaro JM. Lupus erythematosus and toxic epidermal necrolysis. J Am Acad Dermatol 1987; 16: 1265-1267.
17. Wechsler HL, Stavrides A. Systemic lupus erythematosus with anti-Ro antibodies: clinical, histologic and immunologic findings. Report of three cases. J Am Acad Dermatol 1982; 6: 73-83.
18. Grant JM. Annular vesicular lupus erythematosus. Cutis 1981; 28: 90-92.
19. Mutasim DF. Severe subacute cutaneous lupus erythematosus presenting with generalized erythroderma and bullae. J Am Acad Dermatol 2003; 48: 947-949.
20. Nagy E, Balogh E. Bullous form of chronic discoid lupus erythematodes accompanied by LE cell symptoms. Dermatologica 1961; 122: 6-10.
21. Faisant M, Chade-Tremeau V, Machado P. Lupus erythemateux dissemine vesiculo-bulleux: a propos d'un cas. Ann Dermatol Venereol 1991; 118: 619.
22. Fairchild JP, Bacter DL, Vidmar DA. Bullous lupus erythematosus. J Assoc Mil Dermatol 1991; 17: 10.
23. Camisa C, Sharma HM. Vesiculobullous systemic lupus erythematosus. Report of two cases and a review of the literature. J Am Acad Dermatol 1983; 9: 924-933.
24. Harris-Stith R, Erickson QL, Elston DM, David-Bajar K. Bullous eruption: a manifestation of lupus erythematosus. Cutis 2003; 72: 31-37.
25. Gammon WR, Woodley DT, Dole KC, Briggaman RA. Evidence that anti-basement membrane zone antibodies in bullous eruption of systemic lupus erythematosus recognize epidermolysis bullosa acquisita autoantigen. J Invest Dermatol 1985; 84: 472-476.
26. Yoon J, Moon TK, Lee KH, Kim SC. Fatal vascular involvement in systemic lupus erythematosus following epidermolysis bullosa acquisita. Acta Derm Venereol 1995; 75: 143-146.
27. Olansky AJ, Briggaman RA, Gammon WR, Kelly TF, Sams WM, Jr. Bullous systemic lupus erythematosus. J Am Acad Dermatol 1982; 7: 511-520.
28. Chorzelski T, Jablonska S, Blaszczyk M. Immunopathological investigations in the Senear-Usher syndrome (coexistence of pemphigus and lupus erythematosus). Br J Dermatol 1968; 80: 211-217.
29. Cruz PD Jr, Coldiron BM, Sontheimer RD. Concurrent features of cutaneous lupus erythematosus and pemphigus erythematosus following myasthenia gravis and thymoma. J Am Acad Dermatol 1987; 16(Pt 2): 472-480.
30. Jordon RE, Muller SA, Hale WL, Beutner EH. Bullous pemphigoid associated with systemic lupus erythematosus. Arch Dermatol 1969; 99: 17-25.
31. Kumar V, Binder WL, Schotland E, Beutner EH, Chorzelski TP. Coexistence of bullous pemphigoid and systemic lupus erythematosus. Arch Dermatol 1978; 114: 1187-1190.
32. Szabo E, Husz S, Kovacs L. Coexistent atypical bullous pemphigoid and systemic lupus erythematosus. Br J Dermatol 1981; 104: 71-75.
33. Clayton CA, Burnham TK. Systemic lupus erythematosus and coexisting bullous pemphigoid: immunofluorescent investigations. J Am Acad Dermatol 1982; 7: 236-245.
34. Stoll DM, King LE Jr. Association of bullous pemphigoid with systemic lupus erythematosus. Arch Dermatol 1984; 120: 362-366.
35. Miller JF, Downham TF, Chapel TA. Coexistent bullous pemphigoid and systemic lupus erythematosus. Cutis 1978; 21: 368-373.
36. Moncada B. Dermatitis herpetiformis in association with systemic lupus erythematosis. Arch Dermatol 1974; 109: 723-725.
37. Aronson AJ, Soltani K, Aronson IK, Ong RT. Systemic lupus erythematosus and dermatitis herpetiformis: concurrence with Marfan's syndrome. Arch Dermatol 1979; 115: 68-70.
38. Thomas JR III, Su WP. Concurrence of lupus erythematosus and dermatitis herpetiformis. A report of nine cases. Arch Dermatol 1983; 119: 740-745.
39. Lau M, Kaufmann-Grunzinger I, Raghunath M. A case report of a patient with features of systemic lupus erythematosus and linear IgA disease. Br J Dermatol 1991; 124: 498-502.
40. Davies MG, Marks R, Waddington E. Simultaneous systemic lupus erythematosus and dermatitis herpetiformis. Arch Dermatol 1976; 112: 1292-1294.
41. Tuffanelli DL, DuBois EL. Cutaneous manifestations of systemic lupus erythematosus. Arch Dermatol 1964; 90: 377.
42. Tromovitch TA, Hyman AB. Systemic lupus erythematosus with hemorrhagic bullae. Arch Dermatol 1961; 83: 910.
43. Stone JA, Leavell UW Jr. Unusual cells in lupus erythematosus bullae. Arch Dermatol 1976; 112: 1753-1754.
44. Dotson AD, Raimer SS, Pursley TV, Tschen J. Systemic lupus erythematosus occurring in a patient with epidermolysis bullosa acquisita. Arch Dermatol 1981; 117: 422-426.
45. Boh E, Roberts LJ, Lieu TS, Gammon WR, Sontheimer RD. Epidermolysis bullosa acquisita preceding the development of systemic lupus erythematosus. J Am Acad Dermatol 1990; 22: 587-593.
46. Archibald GC. Epidermolysis bullosa dystorphica and systemic lupus erythematosus. Proc R Soc Med 1976; 69: 881-882.
47. Duperrat B, David y Aitken G, Lauret P. Porphyria cutanea tarda and lupus erythematosus in a splenectomized patient. Bull Soc Fr Dermatol Syphiligr 1968; 75: 424.
48. Clemmensen O, Thomsen K. Porphyria cutanea tarda and systemic lupus erythematosus. Arch Dermatol 1982; 118: 160-162.
49. Weatherhead L, Adam J. Discoid lupus erythematosus. Coexistence with porphyria cutanea tarda. Int J Dermatol 1985; 24: 453-455.
50. Nicholson GD, Prussia PR, Garriques S. Coexistence of porphyria cutanea tarda and systemic lupus erythematosus. West Indian Med J 1988; 37: 232-235.
51. Morvay M, Hunyadi J, Koszo F, Kiss M, Dobozy A, Simon N. Coexistence of porphyria cutanea tarda and lupus erythematosus. Dermatol Monatsschr 1989; 175: 20-27.
52. Gibson GE, McEvoy MT. Coexistence of lupus erythematosus and porphyria cutanea tarda in fifteen patients. J Am Acad Dermatol 1998; 38: 569-573.
53. Lee PK, Abrahams I, Bickers DR. Porphyria cutanea tarda occurring in a patient with renal failure, systemic lupus erythematosus and chronic hepatitis C infection treated with hemodialysis. Cutis 1999; 64: 237-239.
54. Sinha A, Dixon N, O'Sullivan MM, Sowden JM. Porphyria cutanea tarda in a patient with systemic lupus erythematosus. Rheumatology (Oxford) 1999; 38: 1166-1168.
55. Buchvald J, Filo V, Horvathova J. IgA-linear dermatosis imitating Lyell syndrome. Bratisl Lek Listy 1987; 88: 211-217.
56. Tran D, Kossard S, Shumack S. Phenytoin-induced linear IgA dermatosis mimicking toxic epidermal necrolysis. Australas J Dermatol 2003; 44: 284-286.
57. Burch JM, Tayal S, Golitz LE, Fitzpatrick JE. Vancomycin-associated linear IgA bullous dermatosis mimicking toxic epidermal necrolysis. J Am Acad Dermatol 2003; 48(suppl.): S56-S57.
58. Moallem HJ, Baqi N, Taningco G et al. Systemic lupus erythematosus presenting as toxic epidermal necrolysis in an adolescent. Int Pediat 2002; 17: 31-33.
59. Berkel AI, Tinaztepe K. Graft-versus-host reaction manifested as toxic epidermal necrolysis in a patient with acute leukemia. Turk J Pediatr 1981; 23: 37-41.
60. De Dobbeleer GD, Ledoux-Corbusier MH, Achten GA. Graft versus host reaction. An ultrastructural study. Arch Dermatol 1975; 111: 1597-1902.
61. Friedman HZ, Arias AM, Catchatourian R, Fretzin DF. Toxic epidermal necrolysis following bone marrow transplantation. Cutis 1984; 34: 158-162.
62. Krueger GRF. Graft-versus-host disease and toxic epidermal necrolysis. Lancet 1973; i: 268-269.
63. McCarty JR, Raimer SS, Jarratt M. Toxic epidermal necrolysis from graft-vs-host disease. Occurrence in a patient with thymic hypoplasia. Am J Dis Child 1978; 132: 282-284.
64. Peck GL, Elias PM, Graw RG. Graft-versus-host reaction and toxic epidermal necrolysis. Lancet 1972; ii: 1151-1153.
65. Peck GL, Herzig GP, Elias PM. Toxic epidermal necrolysis in a patient with graft-vs-host reaction. Arch Dermatol 1972; 105: 561-569.
66. Schauder CS, Hymes SR, Rapini RP, Zipf TF. Vesicular graft-versus-host disease. Int J Dermatol 1992; 31: 509-510.
67. Stone N, Sheerin S, Burge S. Toxic epidermal necrolysis and graft vs. host disease: a clinical spectrum but a diagnostic dilemma. Clin Exp Dermatol 1999; 24: 260-262.
68. Takeda H, Mitsuhashi Y, Kondo S, Kato Y, Tajima K. Toxic epidermal necrolysis possibly linked to hyperacute graft-versus-host disease after allogeneic bone marrow transplantation. J Dermatol 1997; 24: 635-641.
69. Papadopoulos AJ, Schwartz RA, Fekete Z et al. Pseudoporphyria: an atypical variant resembling toxic epidermal necrolysis. J Cutan Med Surg 2001; 5: 479-485.
70. Holler E, Kolb HJ, Moller A et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 1990; 75: 1011-1016.
71. Steffen M, Pichlmeier U, Zander A. Inverse correlation of interleukin-6 with soluble interleukin-6 receptor after transplantation of bone marrow or peripheral blood stem cells. Bone Marrow Transplant 1997; 20: 715-720.
72. Paquet P, Arrese JE, Beguin Y, Pierard GE. Clinicopathological differential diagnosis of drug-induced toxic epidermal necrolysis (Lyell's syndrome) and acute graft-versus-host reaction. Curr Top Pathol 2001; 94: 49-63.
73. Correia O, Delgado L, Barbosa IL, Campilho F, Fleming-Torrinha J. Increased interleukin 10, tumor necrosis factor alpha, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis. J Am Acad Dermatol 2002; 47: 58-62.
74. Mandelcorn R, Shear NH. Lupus-associated toxic epidermal necrolysis: a novel manifestation of lupus? J Am Acad Dermatol 2003; 48: 525-529.
75. Viard I, Wehrli P, Bullani R et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490-493.